Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
Genetic Testing for All Pancreatic Cancer Patients
A study by Dr. Gloria Petersen's research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
Molecular Sequencing Leads to Customized Treatment
When Florida resident Doron Broman was diagnosed with stage IV pancreatic cancer, his decision to get treated in Boston gave him access a PARP inhibitor for maintenance.
Which Is the Best Screening Method for Pancreatic Cancer?
Dr. Aimee Lucas outlines the pros and cons of various screening methods that can be used for pancreatic cancer, and who should be using them.
Aiming to be More than a Statistic
Dr. Paul Silverstein knew that he needed genomic testing, immunotherapy, and a clinical trial in his battle with pancreatic cancer.
Tumor Genetics Research Brings Some Answers for Families at High Risk
Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
New Biopsy Shows Promise For Pancreatic Cancer Patients
Trovagene is developing a liquid biopsy for pancreatic cancer patients, to allow doctors to test for cancer and track treatment response.
